|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-5-16
|
|
pubmed:abstractText |
Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stage groups, conventional prognostic indicators currently fail to predict relapse accurately.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2946-54
|
|
pubmed:meshHeading |
pubmed-meshheading:17504995-Adenocarcinoma,
pubmed-meshheading:17504995-Aged,
pubmed-meshheading:17504995-Female,
pubmed-meshheading:17504995-Gene Expression Profiling,
pubmed-meshheading:17504995-Genes, Neoplasm,
pubmed-meshheading:17504995-Humans,
pubmed-meshheading:17504995-Lung Neoplasms,
pubmed-meshheading:17504995-Male,
pubmed-meshheading:17504995-Middle Aged,
pubmed-meshheading:17504995-Neoplasm Recurrence, Local,
pubmed-meshheading:17504995-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:17504995-Prognosis,
pubmed-meshheading:17504995-Risk,
pubmed-meshheading:17504995-Tumor Markers, Biological
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Gene expression signature predicts recurrence in lung adenocarcinoma.
|
|
pubmed:affiliation |
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia. Jill_E_Larsen@health.qld.gov.au
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
